unapproved substance is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| IUPAC name | {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | Systematic name for GW501516 |
| CAS Registry Number | 317318-70-0 | Unique identifier for the parent compound |
| Molecular formula | C21H18F3NO3S2 | Includes carbon, hydrogen, fluorine, nitrogen, oxygen, and sulfur |
| Molecular weight | 453.5 g/mol | Approximate value for the neutral form |
| Appearance | White to off-white powder | Typical description for purified laboratory material |
=== Supplements === α-KIC has been studied as a nutritional supplement to aid in the performance of strenuous physical activity. Studies have shown that taking ɑ-KIC and its derivatives before acute physical activity led to an increase in muscle work by 10%, as well as a decrease in muscle fatigue during the early phase of the physical activity. When taken with other supplements over a two-week period, such as beta-hydroxy beta-methylbutyrate (HMB), participants reported delayed onset of muscle soreness, as well as other positive effects such as increased muscle girth. Studies have also suggested that ɑ-KIC taken alone did not have any significant positive impacts on physical performance, so it should be taken in conjunction with other ergogenic substances. ɑ-KIC is not available as a supplement on its own, but its decarboxylated form HMB is available in calcium salt capsules or powder.
=== 1960s === 1964: opens first subsidiary, in France 1967: introduces the Super-Q water purification system 1967: establishes German subsidiary 1968: establishes Japanese subsidiary 1968: introduces Pellicon cassette product, for purifying biotherapeutics
Recently, an efficient stepwise solid-phase synthesis of RANTES (24-91) was published. RANTES is a major HIV-suppressive factor produced by CD8+ T Cells. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) induces a NH2-terminal truncation from RANTES (1-91) to RANTES(24-91), which inhibits the infection of monocytes by an M-tropic HIV-1 strain The 68 amino acid of RANTES(24-91) has a high propensity to aggregate. The method combines the advantages of the PEG-based ChemMatrix resin and pseudoproline dipeptides. Direct coupling to pseudoproline monomer. Senko and his colleagues were the first to confirm the effectiveness of pseudoproline derivatives of individual, single residues in polypeptide synthesis. According to literature, the conversion of Ser(ΨPro) was excellent, however the Thr(ΨPro) varied in a wide range. The acylation of Pseudoproline monomer depended also on the chemical nature of the acylating residue. Manne and his colleagues successfully synthesized a human Growth Hormone (hGH)-derived polypeptide that was previously challenging to access, using Ser(ΨPro), while JR10 utilized Thr(ΨPro). Building upon Senko et al.'s work, Szaniszló and co-workers have recently improved the acylating efficiency of Thr(ΨPro) and incorporated it into their continuous flow peptide synthesizer.
Sources: en.wikipedia.org
== Pharmacology == Dihydrocodeine exerts its analgesic action through affinity to predominantly μ-opioid receptor and to lesser extent to κ-opioid receptor and δ-opioid receptor. A 1956 source states that 30 mg of subcutaneous dihydrocodeine is equianalgesic to 10 mg of morphine. Another source states that dihydrocodeine is twice as strong as codeine and the metabolite dihydromorphine is likewise twice as strong as morphine. Dihydrocodeine (DHC) is O-demethylated into dihydromorphine (DHM) by CYP2D6 and N-demethylated into nordihydrocodeine (NDHC) by CYP3A4, summarily yielding nordihydromorphine (NDHM). Dihydrocodeine and its metabolites form 3- and 6-glucuronides. Due to the multidirectional metabolism, as opposed to tramadol and codeine, CYP2D6 activity probably does not influence DHC analgesia. The analgesia is likely achieved by the action of DHC itself, as well as DHC-6-G. DHC appears not to differ between poor and extensive metabolizers in terms of its pain threshold and pupillary reaction effect in spite of major variation in DHM blood levels. DHC-6-G is half as potent as DHC. DHM and DHM-6-G display the highest affinity to μ-opioid receptors, being 70 times as potent as DHC, whereas other metabolites display lesser affinity. DHM-6-G has similar potency as DHM, while DHM-3-G is considerably weaker. Action on δ-opioid receptor is 5-50 weaker compared to μ with the exception of DHC-6-G being twice as strong as DHC. 6-glucuronides possess lesser affinity towards κ-opioid receptors, albeit the affinity of DHC is comparable to codeine, DHM and morphine.
Because of its behavior as a prodrug and its pharmacokinetic differences, lisdexamfetamine has a longer duration of therapeutic effect than immediate-release dextroamphetamine and shows reduced misuse potential. CYP2D6, dopamine β-hydroxylase (DBH), flavin-containing monooxygenase 3 (FMO3), butyrate-CoA ligase (XM-ligase), and glycine N-acyltransferase (GLYAT) are the enzymes known to metabolize amphetamine or its metabolites in humans. Amphetamine has a variety of excreted metabolic products, including 4-hydroxyamphetamine, 4-hydroxynorephedrine, 4-hydroxyphenylacetone, N-hydroxyamphetamine, benzoic acid, hippuric acid, norephedrine, and phenylacetone. Among these metabolites, the active sympathomimetics are 4-hydroxyamphetamine, 4-hydroxynorephedrine, norephedrine, and N-hydroxyamphetamine. The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination. The known metabolic pathways, detectable metabolites, and metabolizing enzymes in humans include the following:
=== Combined elementary and middle schools === Pre-kindergarten through grade 8 schools are essentially combined elementary and middle schools, facilitated in one building. Most of these schools are referred to as "academies" in the school district. The elementary school usually starts at pre-kindergarten and ends at grade 5 and the middle school starts at grade 6 and ends at grade 8. These schools usually offer a slightly enhanced standard of learning and studies have suggested that students have benefited from being in one continuous facility from kindergarten through 8th grade, without having the disruption having to attend a brand new school, for the middle school years. Cora L. Rice Elementary School and G. James Gholson Middle School are not true academies. Both schools are housed in one facility but they operate as two completely separate schools for all intents and purposes.
Sources: en.wikipedia.org
News of UDI was generally received calmly by the local citizenry, apart from some isolated incidents of passing cars being stoned in the black townships outside Bulawayo. A few expected dissenters were arrested, most prominently Leo Baron, Nkomo's lawyer, whose links with black Rhodesians and communists were seen by authorities as "subversive". Baron, the younger brother of the scientist Jacob Bronowski, was arrested nine minutes after UDI was made.
== Overdose == In the event of arsenic poisoning (manifesting as seizures, muscle weakness, confusion), the administration of the drug should be immediately discontinued, and appropriate treatment should be initiated. Penicillamine is commonly used at a dose of up to 1 g/day. For patients unable to take oral medications, dimercaprol can be administered intramuscularly at a dose of 3 mg/kg body weight every 4 hours until life-threatening symptoms subside. In cases of coagulopathy, DMSA is recommended at a dose of 10 mg/kg body weight every 8 hours for 5 days, followed by every 12 hours for 2 weeks. Kidney dialysis may also be considered.
This period is also marked by the appearance of the self-portraits of painters in long tunics and highboots armed with short daggers, such as the painter of the Cave of the Statues or the several painters of the "Cave of the Painters", with often their own identifying labels in Sanskrit. The clothing style and type of these painters has often been described as Sasanian, but has recently been proposed as being rather Hephthalite, due to the similarities with the Hephthalite figures in Dilberjin Tepe, Balalyk Tepe or Bamiyan, and because the Hepthalites did control the Tarim Basin for nearly a century around this time period.
Sources: en.wikipedia.org
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.
It is prohibited by the World Anti-Doping Agency as a hormone and metabolic modulator. Athletes who test positive for GW501516 can face sanctions, including suspensions and loss of results.
Cardarine is a common or trade-style name, while GW501516 is the research code for the same chemical entity. Some sources also use Endurobol or GSK-516. The names refer to the same compound, not distinct drugs.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.